特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
674864

世界の神経因性疼痛管理市場の分析

Global Market Study on Neuropathic Pain Management: Tricyclic Anti-depressants Drug Class Segment Projected to Witness Highest Growth Through 2026

出版日: | 発行: Persistence Market Research | ページ情報: 英文 211 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
世界の神経因性疼痛管理市場の分析
出版日: 2018年07月19日
発行: Persistence Market Research
ページ情報: 英文 211 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の神経因性疼痛管理市場について調査し、市場の概要、薬物クラス・適応症・流通チャネル・地域別の市場規模の推移と予測(過去5年間・今後8年間分)、成長要因および阻害要因の分析、市場機会、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 市場の区分
  • 市場の定義

第3章 世界経済の見通し

  • 国内総生産:地域・国別
  • 医療機器分野の見通し
  • ヘルスケア指標

第4章 市場機会の分析

  • マクロ経済要因
  • 市場機会の分析

第5章 市場の着目点

  • マクロ経済要因
  • 市場機会の分析
  • 成長要因
    • 供給サイドの成長要因
    • 需要サイドの成長要因
  • 阻害要因
  • 市場動向

第6章 マクロ経済の前提条件

第7章 北米の神経因性疼痛管理市場

  • イントロダクション
  • 市場規模の推移と予測:国別(実績値・予測値)
    • 米国
    • カナダ
  • 市場規模の推移と予測:薬物クラス別(実績値・予測値)
    • 三環系抗うつ薬
    • 抗けいれん薬
    • SNRI(セロトニン・ノルアドレナリン再取り込み阻害薬)
    • カプサイシンクリーム
    • 局所麻酔
    • オピオイド
    • ステロイド
    • その他
  • 市場規模の推移と予測:適応症別(実績値・予測値)
    • 糖尿病性ニューロパチー
    • 三叉神経痛
    • 帯状疱疹後神経痛(PHN)
    • 化学療法誘発性末梢ニューロパチー
    • その他
  • 市場規模の推移と予測:流通チャネル別(実績値・予測値)
    • 小売薬局
    • 病院薬局
    • オンライン薬局
  • 市場魅力分析:セグメント別
  • 主要企業の市場集中度
  • 成長要因と阻害要因 - 影響力の分析

第8章 ラテンアメリカの神経因性疼痛管理市場

  • イントロダクション
  • 市場規模の推移と予測:国別(実績値・予測値)
    • アルゼンチン
    • ブラジル
    • メキシコ
    • その他
  • 市場規模の推移と予測:薬物クラス別(実績値・予測値)
  • 市場規模の推移と予測:適応症別(実績値・予測値)
  • 市場規模の推移と予測:流通チャネル別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 主要企業の市場集中度
  • 成長要因と阻害要因 - 影響力の分析

第9章 欧州の神経因性疼痛管理市場分析と予測

  • イントロダクション
  • 市場規模の推移と予測:国別(実績値・予測値)
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • その他
  • 市場規模の推移と予測:薬物クラス別(実績値・予測値)
  • 市場規模の推移と予測:適応症別(実績値・予測値)
  • 市場規模の推移と予測:流通チャネル別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 主要企業の市場集中度
  • 成長要因と阻害要因 - 影響力の分析

第10章 アジア太平洋(中国を除く)の神経因性疼痛管理市場

  • イントロダクション
  • 市場規模の推移と予測:国別(実績値・予測値)
    • 日本
    • インド
    • オーストラリア・ニュージーランド
    • その他
  • 市場規模の推移と予測:薬物クラス別(実績値・予測値)
  • 市場規模の推移と予測:適応症別(実績値・予測値)
  • 市場規模の推移と予測:流通チャネル別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 主要企業の市場集中度
  • 成長要因と阻害要因 - 影響力の分析

第11章 中東・アフリカの神経因性疼痛管理市場

  • イントロダクション
  • 市場規模の推移と予測:国別(実績値・予測値)
    • 湾岸協力会議(GCC)
    • 南アフリカ
    • その他
  • 市場規模の推移と予測:薬物クラス別(実績値・予測値)
  • 市場規模の推移と予測:適応症別(実績値・予測値)
  • 市場規模の推移と予測:流通チャネル別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 主要企業の市場集中度
  • 成長要因と阻害要因 - 影響力の分析

第12章 予測要因:関連性と影響力

第13章 予測の前提条件

第14章 競合分析

  • 市場構造:企業ティア別
  • 競合情勢
  • 競合ベンチマーキング
  • 企業プロファイル
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc
    • Sanofi S.A.
    • GlaxoSmithKline plc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb
    • Biogen Idec, Inc.
    • Baxter Healthcare Corporation
    • Depomed, Inc.

第15章 神経因性疼痛管理の世界市場:地域別

  • イントロダクション/主な所見
  • 市場規模の推移と予測:地域別
  • 市場魅力分析:地域別

第16章 世界の神経因性疼痛管理市場:医薬品クラス別

第17章 世界の神経因性疼痛管理市場:適応症別

第18章 世界の神経因性疼痛管理市場:流通チャネル別

第19章 世界の神経因性疼痛管理市場:分析と予測

  • 市場規模の分析:セグメント別
  • 前年比成長率の分析:セグメント別

第20章 調査方法

図表

List of Tables

  • Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 (1/2)
  • Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 (2/2)
  • Table 03: North America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 04: North America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 05: North America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 06: North America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 07: Latin America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 08: Latin America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 09: Latin America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 10: Latin America Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 11: Europe Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 12: Europe Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 13: Europe Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 14: Europe Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 15: Asia-Pacific Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 16: Asia-Pacific Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 17: Asia-Pacific Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 18: Asia-Pacific Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 19: MEA Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 20: MEA Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 21: MEA Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 22: MEA Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 23: Global Neuropathic Pain Management Size (US$ Mn) 2012-2016 and Forecast 2018-2026 By Region,
  • Table 24: Global Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 25: Global Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication
  • Table 26: Global Neuropathic Pain Management Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

List of Figures

  • Figure 01: Global Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 02: Global Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 03: Global Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 05: Global Neuropathic Pain Management Market Value Share By Region (2018 E)
  • Figure 06: North America Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 07: North America Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 08: North America Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 09: North America Neuropathic Pain Management Market Value Share By Country (2018 E)
  • Figure 10: North America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 11: North America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 12: U.S. Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 13: U.S. Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 14: Canada Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 15: Canada Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 16: North America Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 17: North America Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 18: North America Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 19: North America Neuropathic Pain Management Market Attractiveness Analysis By Country, 2018-2026
  • Figure 20: Latin America Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 21: Latin America Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 22: Latin America Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 23: Latin America Neuropathic Pain Management Market Value Share By Country (2018 E)
  • Figure 24: Latin America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 25: Latin America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 26: Brazil Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 27: Brazil Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 28: Mexico Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 29: Mexico Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 30: Argentina Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 31: Argentina Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 32: Rest of Latin America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 33: Rest of Latin America Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 34: Latin America Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 35: Latin America Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 36: Latin America Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 37: Latin America Neuropathic Pain Management Market Attractiveness Analysis By Country, 2018-2026
  • Figure 38: Europe Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 39: Europe Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 40: Europe Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 41: Europe Neuropathic Pain Management Market Value Share By Country (2018 E)
  • Figure 42: Europe Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 43: Europe Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 44: U.K. Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 45: U.K. Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 46: Germany Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-201754
  • Figure 47: Germany Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 48: France Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 49: France Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 50: Italy Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 51: Italy Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 52: Spain Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 53: Spain Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 54: Russia Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 55: Russia Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 56: Rest of Europe Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 57: Rest of Europe Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 58: Europe Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 59: Europe Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 60: Europe Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 61: Europe Neuropathic Pain Management Market Attractiveness Analysis By Country, 2018-2026
  • Figure 62: Asia-Pacific Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 63: Asia-Pacific Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 64: Asia-Pacific Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 65: Asia-Pacific Neuropathic Pain Management Market Value Share By Country (2018 E)
  • Figure 66: Asia-Pacific Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 67: Asia-Pacific Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 68: Japan Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 69: Japan Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 70: China Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 71: China Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 72: India Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 73: India Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 74: Australia and New Zealand Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 75: Australia and New Zealand Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 76: ASEAN Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 77: ASEAN Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 78: Rest of Asia-Pacific Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 79: Rest of Asia-Pacific Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 80: Asia-Pacific Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 81: Asia-Pacific Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 82: Asia-Pacific Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 83: Asia-Pacific Neuropathic Pain Management Market Attractiveness Analysis By Country, 2018-2026
  • Figure 84: MEA Neuropathic Pain Management Market Value Share By Drug Class (2018 E)
  • Figure 85: MEA Neuropathic Pain Management Market Value Share By Indication (2018 E)
  • Figure 86: MEA Neuropathic Pain Management Market Value Share By Distribution Channel (2018 E)
  • Figure 87: MEA Neuropathic Pain Management Market Value Share By Country (2018 E)
  • Figure 88: MEA Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 89: MEA Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 90: South Africa Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 91: South Africa Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 92: GCC Countries Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 93: GCC Countries Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 94: Rest of MEA Neuropathic Pain Management Market Value Analysis (US$ Mn), 2013-2017
  • Figure 95: Rest of MEA Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 96: MEA Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 97: MEA Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 98: MEA Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 99: MEA Neuropathic Pain Management Market Attractiveness Analysis By Country, 2018-2026
  • Figure 100: Global Neuropathic Pain Management Market Share Analysis (%), By Region, 2018 & 2026
  • Figure 101: Global Neuropathic Pain Management Market Y-o-Y Analysis (%), By Region, 2018-2026
  • Figure 102: Global Neuropathic Pain Management Market Attractiveness Analysis By Region, 2018-2026
  • Figure 103: Global Neuropathic Pain Management Market Share Analysis (%), By Drug Class, 2018 & 2026
  • Figure 104: Global Neuropathic Pain Management Market Y-o-Y Analysis (%), By Drug Class, 2018-2026
  • Figure 105: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Tricyclic Anti Depressants, 2013-2017
  • Figure 106: Global Tricyclic Neuropathic Pain Management Market Value Analysis (US$ Mn), By Tricyclic Anti Depressants, 2018-2026
  • Figure 107: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Anticonvulsants, 2013-2017
  • Figure 108: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Anticonvulsants, 2018-2026
  • Figure 109: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By SNRI's, 2013-2017
  • Figure 110: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By SNRI's, 2018-2026
  • Figure 111: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Capsaicin Cream, 2013-2017
  • Figure 112: Global Capsaicin Cream Neuropathic Pain Management Market Value Analysis (US$ Mn), By Capsaicin Cream, 2018-2026
  • Figure 113: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Local Anesthesia 2013-2017
  • Figure 114: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Local Anesthesia , 2018-2026
  • Figure 115: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Opioids 2013-2017
  • Figure 116: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Opioids, 2018-2026
  • Figure 117: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Steroids , 2013-2017
  • Figure 118: Global Neuropathic Pain Management Market Value Analysis (US$ Mn),By Steroids, 2018-2026
  • Figure 119: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), by Others, 2013-2017
  • Figure 120: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Others, 2018-2026
  • Figure 121: Global Neuropathic Pain Management Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 122: Global Neuropathic Pain Management Market Share Analysis (%), By Indication , 2018 & 2026
  • Figure 123: Global Neuropathic Pain Management Market Y-o-Y Analysis (%), By Indication , 2018-2026
  • Figure 124: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Diabetic Neuropathy, 2013-2017
  • Figure 125: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Diabetic Neuropathy, 2018-2026
  • Figure 126: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Trigeminal Neuralgia, 2013-2017
  • Figure 127: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Trigeminal Neuralgia, 2018-2026
  • Figure 128: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Post-Herpetic Neuralgia, 2013-2017
  • Figure 129: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Post-Herpetic Neuralgia, 2018-2026
  • Figure 130: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By CIPN, 2013-2017
  • Figure 131: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By CIPN, 2018-2026
  • Figure 132: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Post-Herpetic Neuralgia, 2013-2017
  • Figure 133: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Post-Herpetic Neuralgia, 2018-2026
  • Figure 134: Global Neuropathic Pain Management Market Attractiveness Analysis By Indication, 2018-2026
  • Figure 135: Global Neuropathic Pain Management Market Share Analysis (%), By Distribution Channel, 2018 & 2026
  • Figure 136: Global Neuropathic Pain Management Market Y-o-Y Analysis (%), By Distribution Channel, 2018-2026
  • Figure 137: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Retail Pharmacies, 2013-2017
  • Figure 138: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Retail Pharmacies, 2018-2026
  • Figure 139: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Hospital Pharmacies, 2013-2017
  • Figure 140: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Hospital Pharmacies, 2018-2026
  • Figure 141: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Online Pharmacies, 2013-2017
  • Figure 142: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), By Online Pharmacies, 2018-2026
  • Figure 143: Global Neuropathic Pain Management Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 144: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), 2012-2016
  • Figure 145: Global Neuropathic Pain Management Market Value Analysis (US$ Mn), 2018-2026
  • Figure 146: Global Neuropathic Pain Management Market Absolute $ Opportunity, 2018 - 2026
目次

This Persistence Market Research (PMR) report examines the 'Global Neuropathic Pain Management Market' for the period 2018-2026. The primary objective of the report is to offer updates and information related to market opportunities in the global neuropathic pain management market.

The Neuropathic Pain Management Market is Segmented as Follows:

  • Neuropathic Pain Management Market, by Drug Class
  • Neuropathic Pain Management Market, by Indication
  • Neuropathic Pain Management Market, by Distribution Channel
  • Neuropathic Pain Management Market, by Region

This report covers the global neuropathic pain management market performance in terms of revenue contribution from various segments. The report begins with an overview of the neuropathic pain management and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the neuropathic pain management market along with detailing its opportunity analysis.

The global neuropathic pain management market is segmented based on drug class, indication, distribution channel and region. On the basis of drug class, the market has been segmented as tricyclic anti-depressants anticonvulsants, serotonin-norepinephrine reuptake inhibitor, capsaicin cream, local anaesthesia, opioids, steroids and others.

On the basis of indication, the market is segmented as diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others.

On the basis of distribution channel, the market is segmented as hospital pharmacies, retail pharmacies and online pharmacies.

A detailed analysis has been provided for each region in terms of market size, BPS analysis, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The regional market dynamics provide the key growth driver, restraints, and trends pertaining to each region. The forecast of the neuropathic pain management market by country, drug class, indication, distribution channel are represented in the tabular form for each region. This section also helps to understand the opportunity of the neuropathic pain management market in major countries by each segment.

In the next section of the report, the 'Competitive Landscape' is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players in the neuropathic pain management market are also provided in the report, which highlights company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 2018-2026 and sets the forecast within the context of the neuropathic pain management market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections - by drug class, indication, distribution channel - evaluate the historic market analysis for the period of 2013-2017 and growth prospects of the neuropathic pain management market for the period 2018-2026. We have considered 2016 as the base year and provided data for the forecast period.

The final section of report represents the global scenario for the neuropathic pain management market along with Y-o-Y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the neuropathic pain management market and the opportunity analysis for each year over the forecast period.

Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the neuropathic pain management market over 2018-2026. While forecasting the market size, we have considered the impact of several factors such product approvals for neuropathic pain management, R&D investment by major players, pipeline analysis, penetration of products in different distribution channel, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy
  • 2.3. Inclusion and Exclusion

3. Global Economic Outlook

  • 3.1. Gross Domestic Product by Region & Country, 2006 - 2021
  • 3.2. Medical Devices Sector Outlook
  • 3.3. Healthcare Indicators

4. Neuropathic Pain Management Market Opportunity Analysis

  • 4.1. Macro-Economic Factors
  • 4.2. Opportunity Analysis

5. Market View Point

  • 5.1. Macro-Economic Factors
  • 5.2. Opportunity Analysis
  • 5.3. Drivers
    • 5.3.1. Supply Side Drivers
    • 5.3.2. Demand Side Drivers
  • 5.4. Restraints
  • 5.5. Trends

6. Macroeconomic Assumptions

7. North America Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 7.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 7.4.1. Tricyclic Anti-Depressants
    • 7.4.2. Anticonvulsants
    • 7.4.3. SNRI's
    • 7.4.4. Capsaicin Cream
    • 7.4.5. Local Anesthesia
    • 7.4.6. Opioids
    • 7.4.7. Steroids
    • 7.4.8. Others
  • 7.5. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 7.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 7.6.1. Diabetic Neuropathy
    • 7.6.2. Trigeminal Neuralgia
    • 7.6.3. Post-Herpetic Neuralgia
    • 7.6.4. Chemotherapy-Induced Peripheral Neuropathy
    • 7.6.5. Others
  • 7.7. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 7.8.1. Retail Pharmacies
    • 7.8.2. Hospital Pharmacies
    • 7.8.3. Online Pharmacies
  • 7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 7.10. Market Attractiveness Analysis
    • 7.10.1. By Country
    • 7.10.2. By Drug Class
    • 7.10.3. By Indication
    • 7.10.4. By Distribution Channel
  • 7.11. Key Market Participants - Intensity Mapping
  • 7.12. Drivers and Restraints - Impact Analysis

8. Latin America Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

  • 8.1. Introduction
  • 8.2. Regional Market Trends
  • 8.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 8.3.1. Argentina
    • 8.3.2. Brazil
    • 8.3.3. Mexico
    • 8.3.4. Rest of Latin America
  • 8.4. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 8.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 8.5.1. Tricyclic Anti-Depressants
    • 8.5.2. Anticonvulsants
    • 8.5.3. SNRI's
    • 8.5.4. Capsaicin Cream
    • 8.5.5. Local Anesthesia
    • 8.5.6. Opioids
    • 8.5.7. Steroids
    • 8.5.8. Others
  • 8.6. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 8.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 8.7.1. Diabetic Neuropathy
    • 8.7.2. Trigeminal Neuralgia
    • 8.7.3. Post-Herpetic Neuralgia
    • 8.7.4. Chemotherapy-Induced Peripheral Neuropathy
    • 8.7.5. Others
  • 8.8. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 8.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 8.9.1. Retail Pharmacies
    • 8.9.2. Hospital Pharmacies
    • 8.9.3. Online Pharmacies
  • 8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 8.11. Market Attractiveness Analysis
    • 8.11.1. By Country
    • 8.11.2. By Drug Class
    • 8.11.3. By Indication
    • 8.11.4. By Distribution Channel
  • 8.12. Key Market Participants - Intensity Mapping
  • 8.13. Drivers and Restraints - Impact Analysis

9. Europe Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

Market forecast and analysis in Germany, U.K., France, Italy, Spain, Russia and rest of Europe

  • 9.1. Introduction
  • 9.2. Regional Market Trends
  • 9.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 9.3.1. Germany
    • 9.3.2. U.K.
    • 9.3.3. France
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Russia
    • 9.3.7. Rest of Europe
  • 9.4. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 9.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 9.5.1. Tricyclic Anti-Depressants
    • 9.5.2. Anticonvulsants
    • 9.5.3. SNRI's
    • 9.5.4. Capsaicin Cream
    • 9.5.5. Local Anesthesia
    • 9.5.6. Opioids
    • 9.5.7. Steroids
    • 9.5.8. Others
  • 9.6. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 9.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 9.7.1. Diabetic Neuropathy
    • 9.7.2. Trigeminal Neuralgia
    • 9.7.3. Post-Herpetic Neuralgia
    • 9.7.4. Chemotherapy-Induced Peripheral Neuropathy
    • 9.7.5. Others
  • 9.8. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 9.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 9.9.1. Retail Pharmacies
    • 9.9.2. Hospital Pharmacies
    • 9.9.3. Online Pharmacies
  • 9.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 9.11. Market Attractiveness Analysis
    • 9.11.1. By Country
    • 9.11.2. By Drug Class
    • 9.11.3. By Indication
    • 9.11.4. By Distribution Channel
  • 9.12. Key Market Participants - Intensity Mapping
  • 9.13. Drivers and Restraints - Impact Analysis

10. Asia-Pacific Excluding China Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

  • 10.1. Introduction
  • 10.2. Regional Market Trends
  • 10.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 10.3.1. Japan
    • 10.3.2. India
    • 10.3.3. Australia and New Zealand
    • 10.3.4. Rest of Asia Pacific
  • 10.4. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 10.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 10.5.1. Tricyclic Anti-Depressants
    • 10.5.2. Anticonvulsants
    • 10.5.3. SNRI's
    • 10.5.4. Capsaicin Cream
    • 10.5.5. Local Anesthesia
    • 10.5.6. Opioids
    • 10.5.7. Steroids
    • 10.5.8. Others
  • 10.6. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 10.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 10.7.1. Diabetic Neuropathy
    • 10.7.2. Trigeminal Neuralgia
    • 10.7.3. Post-Herpetic Neuralgia
    • 10.7.4. Chemotherapy-Induced Peripheral Neuropathy
    • 10.7.5. Others
  • 10.8. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 10.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 10.9.1. Retail Pharmacies
    • 10.9.2. Hospital Pharmacies
    • 10.9.3. Online Pharmacies
  • 10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 10.11. Market Attractiveness Analysis
    • 10.11.1. By Country
    • 10.11.2. By Drug Class
    • 10.11.3. By Indication
    • 10.11.4. By Distribution Channel
  • 10.12. Key Market Participants - Intensity Mapping
  • 10.13. Drivers and Restraints - Impact Analysis

11. Middle East & Africa Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

Market forecast and analysis in GCC Countries, South Africa, and rest of MEA

  • 11.1. Introduction
  • 11.2. Key Regulations
  • 11.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 11.3.1. GCC Countries
    • 11.3.2. South Africa
    • 11.3.3. Rest of MEA
  • 11.4. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 11.5. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 11.5.1. Tricyclic Anti-Depressants
    • 11.5.2. Anticonvulsants
    • 11.5.3. SNRI's
    • 11.5.4. Capsaicin Cream
    • 11.5.5. Local Anesthesia
    • 11.5.6. Opioids
    • 11.5.7. Steroids
    • 11.5.8. Others
  • 11.6. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 11.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 11.7.1. Diabetic Neuropathy
    • 11.7.2. Trigeminal Neuralgia
    • 11.7.3. Post-Herpetic Neuralgia
    • 11.7.4. Chemotherapy-Induced Peripheral Neuropathy
    • 11.7.5. Others
  • 11.8. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 11.9. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 11.9.1. Retail Pharmacies
    • 11.9.2. Hospital Pharmacies
    • 11.9.3. Online Pharmacies
  • 11.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Country
    • 11.11.2. By Drug Class
    • 11.11.3. By Indication
    • 11.11.4. By Distribution Channel
  • 11.12. Key Market Participants - Intensity Mapping
  • 11.13. Drivers and Restraints - Impact Analysis

12. Forecast Factors: Relevance and Impact

13. Forecast Assumptions

14. Competition Analysis

  • 14.1. Market Structure by Tier of Companies
  • 14.2. Competition Dashboard
  • 14.3. Competition Benchmarking
  • 14.4. Company Deep Dive
    • 14.4.1. Pfizer Inc.
      • 14.4.1.1. Overview
      • 14.4.1.2. Product and Technology Portfolio
      • 14.4.1.3. Production Footprint
      • 14.4.1.4. Sales Footprint
      • 14.4.1.5. Channel Footprint
      • 14.4.1.6. Strategy
        • 14.4.1.6.1. Marketing Strategy
        • 14.4.1.6.2. Product Strategy
        • 14.4.1.6.3. Channel Strategy
    • 14.4.2. Johnson & Johnson Services, Inc
      • 14.4.2.1. Overview
      • 14.4.2.2. Product and Technology Portfolio
      • 14.4.2.3. Production Footprint
      • 14.4.2.4. Sales Footprint
      • 14.4.2.5. Channel Footprint
      • 14.4.2.6. Strategy
        • 14.4.2.6.1. Marketing Strategy
        • 14.4.2.6.2. Product Strategy
        • 14.4.2.6.3. Channel Strategy
    • 14.4.3. Sanofi S.A.
      • 14.4.3.1. Overview
      • 14.4.3.2. Product and Technology Portfolio
      • 14.4.3.3. Production Footprint
      • 14.4.3.4. Sales Footprint
      • 14.4.3.5. Channel Footprint
      • 14.4.3.6. Strategy
        • 14.4.3.6.1. Marketing Strategy
        • 14.4.3.6.2. Product Strategy
        • 14.4.3.6.3. Channel Strategy
    • 14.4.4. GlaxoSmithKline plc.
      • 14.4.4.1. Overview
      • 14.4.4.2. Product and Technology Portfolio
      • 14.4.4.3. Production Footprint
      • 14.4.4.4. Sales Footprint
      • 14.4.4.5. Channel Footprint
      • 14.4.4.6. Strategy
        • 14.4.4.6.1. Marketing Strategy
        • 14.4.4.6.2. Product Strategy
        • 14.4.4.6.3. Channel Strategy
    • 14.4.5. Eli Lilly and Company
      • 14.4.5.1. Overview
      • 14.4.5.2. Product and Technology Portfolio
      • 14.4.5.3. Production Footprint
      • 14.4.5.4. Sales Footprint
      • 14.4.5.5. Channel Footprint
      • 14.4.5.6. Strategy
        • 14.4.5.6.1. Marketing Strategy
        • 14.4.5.6.2. Product Strategy
        • 14.4.5.6.3. Channel Strategy
    • 14.4.6. Bristol-Myers Squibb
      • 14.4.6.1. Overview
      • 14.4.6.2. Product and Technology Portfolio
      • 14.4.6.3. Production Footprint
      • 14.4.6.4. Sales Footprint
      • 14.4.6.5. Channel Footprint
      • 14.4.6.6. Strategy
        • 14.4.6.6.1. Marketing Strategy
        • 14.4.6.6.2. Product Strategy
        • 14.4.6.6.3. Channel Strategy
    • 14.4.7. Biogen Idec, Inc.
      • 14.4.7.1. Overview
      • 14.4.7.2. Product and Technology Portfolio
      • 14.4.7.3. Production Footprint
      • 14.4.7.4. Sales Footprint
      • 14.4.7.5. Channel Footprint
      • 14.4.7.6. Strategy
        • 14.4.7.6.1. Marketing Strategy
        • 14.4.7.6.2. Product Strategy
        • 14.4.7.6.3. Channel Strategy
    • 14.4.8. Baxter Healthcare Corporation
      • 14.4.8.1. Overview
      • 14.4.8.2. Product and Technology Portfolio
      • 14.4.8.3. Production Footprint
      • 14.4.8.4. Sales Footprint
      • 14.4.8.5. Channel Footprint
      • 14.4.8.6. Strategy
        • 14.4.8.6.1. Marketing Strategy
        • 14.4.8.6.2. Product Strategy
        • 14.4.8.6.3. Channel Strategy
    • 14.4.9. Depomed, Inc.
      • 14.4.9.1. Overview
      • 14.4.9.2. Product and Technology Portfolio
      • 14.4.9.3. Production Footprint
      • 14.4.9.4. Sales Footprint
      • 14.4.9.5. Channel Footprint
      • 14.4.9.6. Strategy
        • 14.4.9.6.1. Marketing Strategy
        • 14.4.9.6.2. Product Strategy
        • 14.4.9.6.3. Channel Strategy

15. Global Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026, By Region

  • 15.1. Introduction/Key Findings
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2017
  • 15.3. Market Size (US$ Mn) Forecast By Region, 2018-2026
    • 15.3.1. North America
    • 15.3.2. Latin America
    • 15.3.3. Europe
    • 15.3.4. Asia-Pacific
    • 15.3.5. Middle East & Africa
  • 15.4. Market Attractiveness Analysis By Region

16. Global Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

  • 16.1. Introduction/Key Findings
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class 2013-2017
    • 16.2.1. Tricyclic Anti-Depressants
    • 16.2.2. Anticonvulsants
    • 16.2.3. SNRI's
    • 16.2.4. Capsaicin Cream
    • 16.2.5. Local Anesthesia
    • 16.2.6. Opioids
    • 16.2.7. Steroids
    • 16.2.8. Others
  • 16.3. Market Size (US$ Mn) Forecast By Drug Class 2018-2026
  • 16.4. Market Attractiveness Analysis By Drug Class

17. Global Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026, By Indication

  • 17.1. Introduction/Key Findings
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2017
    • 17.2.1. Diabetic Neuropathy
    • 17.2.2. Trigeminal Neuralgia
    • 17.2.3. Post-Herpetic Neuralgia
    • 17.2.4. Chemotherapy-Induced Peripheral Neuropathy
    • 17.2.5. Others
  • 17.3. Market Size (US$ Mn) Forecast By Indication, 2018-2026
  • 17.4. Market Attractiveness Analysis By Indication

18. Global Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

  • 18.1. Introduction/Key Findings
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 18.2.1. Retail Pharmacies
    • 18.2.2. Hospital Pharmacies
    • 18.2.3. Online Pharmacies
  • 18.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 18.4. Market Attractiveness Analysis By Distribution Channel

19. Global Neuropathic Pain Management Market Analysis 2013-2017 and Forecast 2018-2026

  • 19.1. Market Value Share Analysis By All Segment
  • 19.2. Y-o-Y Growth Analysis By All Segment
  • 19.3. Absolute $ Opportunity

20. Research Methodology

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.